Segui
Flavia Michelini
Flavia Michelini
Associate Director, Translational Medicine at AstraZeneca
Email verificata su astrazeneca.com - Home page
Titolo
Citata da
Citata da
Anno
Site-specific DICER and DROSHA RNA products control the DNA-damage response
S Francia, F Michelini, A Saxena, D Tang, M De Hoon, V Anelli, M Mione, ...
Nature 488 (7410), 231-235, 2012
5772012
Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks
F Michelini, S Pitchiaya, V Vitelli, S Sharma, U Gioia, F Pessina, M Cabrini, ...
Nature Cell Biology, 2017
3362017
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ...
Cancer discovery 10 (5), 674-687, 2020
1732020
A damaged genome’s transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks
F Iannelli, A Galbiati, I Capozzo, Q Nguyen, B Magnuson, F Michelini, ...
Nature communications 8 (1), 15656, 2017
992017
From “cellular” RNA to “smart” RNA: multiple roles of RNA in genome stability and beyond
F Michelini, AP Jalihal, S Francia, C Meers, ZT Neeb, F Rossiello, U Gioia, ...
Chemical reviews 118 (8), 4365-4403, 2018
822018
Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs
U Gioia, S Francia, M Cabrini, S Brambillasca, F Michelini, ...
Scientific reports 9 (1), 6460, 2019
682019
MRE11-RAD50-NBS1 Complex Is Sufficient to Promote Transcription by RNA Polymerase II at Double-Strand Breaks by Melting DNA Ends
S Sharma, R Anand, X Zhang, S Francia, F Michelini, A Galbiati, ...
Cell Reports 34 (1), 108565, 2021
542021
Prolonged lifespan with enhanced exploratory behavior in mice overexpressing the oxidized nucleoside triphosphatase hMTH1
G De Luca, I Ventura, V Sanghez, MT Russo, MA Ajmone‐Cat, E Cacci, ...
Aging cell 12 (4), 695-705, 2013
452013
Bystander effect of antibody–drug conjugates: fact or fiction?
F Giugliano, C Corti, P Tarantino, F Michelini, G Curigliano
Current oncology reports 24 (7), 809-817, 2022
422022
DROSHA RNA products control the DNA-damage response
S Francia, F Michelini, A Saxena, D Tang, M De Hoon, V Anelli, M Mione, ...
Nature 488 (7410), 231-235, 2012
352012
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors
Y Cai, G Xu, F Wu, F Michelini, C Chan, X Qu, P Selenica, E Ladewig, ...
Cancer research 81 (9), 2470-2480, 2021
232021
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020; 10: 674–687. doi: 10.1158/2159-8290
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ...
CD-20-0215.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
20
Cytogenetic analysis of human cells reveals specific patterns of DNA damage in replicative and oncogene‐induced senescence
G Falcone, A Mazzola, F Michelini, G Bossi, F Censi, MG Biferi, ...
Aging Cell 12 (2), 312-315, 2013
102013
RNase A treatment and reconstitution with DNA damage response RNA in living cells as a tool to study the role of non-coding RNA in the formation of DNA damage response foci
F Michelini, F Rossiello, FA di Fagagna, S Francia
Nature Protocols, 1, 2019
82019
The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation
E Ladewig, F Michelini, K Jhaveri, P Castel, J Carmona, L Fairchild, ...
Cancer research 82 (12), 2269-2280, 2022
62022
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov, 2020, 10 (5): 674-687. doi: 10.1158/2159-8290
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai
CD-20-0215, 0
6
Complete remission of widely metastatic human epidermal growth factor receptor 2–amplified pancreatic adenocarcinoma after precision immune and targeted therapy with …
DA King, AR Smith, G Pineda, M Nakano, F Michelini, SP Goedegebuure, ...
JCO Precision Oncology 7, e2100489, 2023
52023
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the …
BT Li, F Meric-Bernstam, A Bardia, Y Naito, S Siena, PG Aftimos, ...
Annals of Oncology 34, S459-S460, 2023
32023
Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling
DA King, AR Smith, G Pineda, M Nakano, F Michelini, SP Goedegebuure, ...
medRxiv, 2021.12. 16.21267326, 2021
12021
RNA products and uses thereof
FDA Di Fagagna, S Francia, F Michelini, F Rossiello
US Patent 9,708,606, 2017
1*2017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20